RxDoctor Payments Data

Linh Dang, MD

Neurology · The Woodlands, TXNPI 1154425213

Payments from drug & device makers

$9,021in general payments, 2019–2025

Across 295 payments — averaging $30.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • MDD US Operations, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$986
  • Neurocrine Biosciences, Inc.$931
  • Medtronic$724
  • Novartis$381
  • plus $3K from 38 others

What the payments were for

  • Speaking & faculty fees$1281%
  • Travel & lodging$94310%
  • Food & beverage$7,94988%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,021 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$55,753
Medicare patients
155
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate21$197,553
IngrezzaValbenazine Tosylate11$91,267
RytaryCarbidopa/Levodopa55$51,949
NeuproRotigotine13$13,024
Dalfampridine ErDalfampridine17$10,593
Rivastigmine30$8,016
Carbidopa-Levodopa ErCarbidopa/Levodopa57$3,760
Memantine Hcl61$3,157
RivastigmineRivastigmine Tartrate41$2,515
Carbidopa-LevodopaCarbidopa/Levodopa110$2,388
Donepezil Hcl157$2,159
Galantamine Hbr19$1,849
Gabapentin164$1,837
Pregabalin66$1,508
Venlafaxine Hcl ErVenlafaxine Hcl70$1,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$99$197,55321 claims
Neurocrine Biosciences, Inc.Ingrezza$931$91,26711 claims
UCB, Inc.Neupro$101$13,02413 claims
Upsher-smith Laboratories LLCTopiramate$25$26832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →